#Azacitidine
25 drug-shortage status changes at the FDA in the past week. Most recent: Azacitidine Injection.

FDA shortage, label and recall data -- live and queryable by any AI: gateway.pipeworx.io
November 13, 2026 at 1:30 PM
DNA methylation at diagnosis could help predict azacitidine response in myelodysplastic syndromes, outperforming gene activity alone. Routine clinical use still requires further research. doi.org/hcr2ds
Researchers identify DNA marker that could predict treatment response in myelodysplastic syndromes
DNA methylation patterns present at diagnosis could help predict which patients with myelodysplastic syndromes (MDS) will respond to azacitidine.
medicalxpress.com
November 10, 2026 at 12:20 PM
InnoCare Doses First Patient in Phase III Leukemia Trial Against Venetoclax

Armed Forces Institute of Pathology / Public domain InnoCare Pharma has dosed the first patient in a Phase III trial in China comparing its experimental leukemia drug mesutoclax plus azacitidine with venetoclax plus…
InnoCare Doses First Patient in Phase III Leukemia Trial Against Venetoclax
Armed Forces Institute of Pathology / Public domain InnoCare Pharma has dosed the first patient in a Phase III trial in China comparing its experimental leukemia drug mesutoclax plus azacitidine with venetoclax plus azacitidine. The head-to-head study is enrolling older or medically unfit patients with previously untreated acute myeloid leukemia, the company said in a release issued November 8 at 8:33 p.m.
jbiznews.com
November 9, 2026 at 6:02 AM
Response to azacitidine and the TIM-3 inhibitor, sabatolimab, in MDS and CMML is associated with distinct immune and antigen-presentation states https://www.biorxiv.org/content/10.64898/2026.11.04.764360v1
November 5, 2026 at 12:47 PM
Response to azacitidine and the TIM-3 inhibitor, sabatolimab, in MDS and CMML is associated with distinct immune and antigen-presentation states https://www.biorxiv.org/content/10.64898/2026.11.04.764360v1
November 5, 2026 at 12:47 PM
Response to azacitidine and the TIM-3 inhibitor, sabatolimab, in MDS and CMML is associated with distinct immune and antigen-presentation states #SingleCell 🧪🧬🖥️
https://www.biorxiv.org/content/10.64898/2026.11.04.764360v1
November 5, 2026 at 2:01 PM
An AML diagnosis at 72 used to come with a 1970s playbook: brutal chemo or hospice math. Venetoclax rewrote it — a pill that disarms leukemia cells by blocking BCL-2, the bodyguard protein keeping their built-in suicide switch shut. Paired with azacitidine, response rates in older patients went…
November 6, 2026 at 2:09 AM
#APVO Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Fro…

https://www.stocktitan.net/news/APVO/aptevo-achieves-key-clinical-development-objective-significantly-iv41i7mx8x54.html?utm_source=stocktitan-bluesky&utm_medium=social
Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
Aptevo Therapeutics (APVO) reported fewer infusion-related reactions with mipletamig after refining the initial dosing regimen in its ongoing RAINIER study. The study evaluates mipletamig with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. Aptevo described the reduction as substantial and reported favorable findings for cytokine release syndrome, a potentially serious inflammatory reaction.Previously reported findings included remission responses in TP53-mutated AML and patients advancing to stem cell transplantation. The dosing findings do not establish improved efficacy or treatment persistence. Aptevo expects to complete the current study by year-end 2026, conduct regulatory interactions and initiate Phase 2 development in 2027. Mipletamig data will be presented at the American Society of Hematology meeting on December 12–15, 2026.
www.stocktitan.net
November 5, 2026 at 1:30 PM
The combination of ziftomenib with venetoclax and azacitidine demonstrated promising efficacy among patients with relapsed/refractory (R/R) NPM1-mutated acute myeloid leukemia (AML).

See the data here: https://bit.ly/4A1K1Gb
October 29, 2026 at 11:01 PM
Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML: doi.org/10.1172/jci....
JCI Insight - Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML
Research ArticleCell biologyHematology Open Access | 10.1172/jci.insight.205218
buff.ly
October 27, 2026 at 4:08 PM
🚨 $APVO
On October 26, 2026, Aptevo Therapeutics Inc. issued a press release announcing ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine.
SEC Filing: APVO
Click to view the official SEC document.
www.sec.gov
October 26, 2026 at 12:13 PM
#APVO Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell…

https://www.stocktitan.net/news/APVO/aptevo-reports-mipletamig-combination-therapy-enabled-21-of-z0rxkzoymu4o.html?utm_source=stocktitan-bluesky&utm_medium=social
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
Aptevo Therapeutics (APVO) reported that 21% of evaluable frontline acute myeloid leukemia patients advanced to stem cell transplant after mipletamig combination treatment.Ten of 47 patients treated with mipletamig, venetoclax and azacitidine proceeded to donor stem cell transplantation, a potentially curative option. Nine were from the ongoing Phase 1b RAINIER trial and one from a completed dose expansion trial. These patients were initially considered unfit for intensive induction chemotherapy. Comparisons with historical venetoclax and azacitidine results are limited by differences in populations, study design and follow-up.RAINIER is a Phase 1b/2 study whose current stage evaluates mipletamig dosing. Aptevo expects to complete that work by year-end 2026 and discuss next steps with regulators in the first half of 2027.
www.stocktitan.net
October 26, 2026 at 12:05 PM
🧬 Excited to share our new study in @JCI_Insight!
We show that stabilizing PP2A-B56α overcome venetoclax–azacitidine resistance in acute myeloid leukemia by targeting mitochondrial metabolism.
Great collaboration with teams in Navarra and the University of Michigan!
insight.jci.org/articles/vie...
JCI Insight - Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML
insight.jci.org
October 23, 2026 at 8:06 PM
Roberta Buono, Dennis Juarez, Madhuri Paul, Sarah J Skuli, Ian B Wong, Ishita Tarnekar, Zhili Ying, Izabelle Marie F Le, Wen-Pin Chen, Min Zhang, Gerald Wertheim, A'ishah Bakayoko, Marisa Kruidenier, Dequina A Nicholas, Pankaj Gupta, Said M Sebti, Marina Konopleva, Angela G Fleischman, et al.
Pitavastatin counteracts venetoclax resistance mechanisms including <em>TP53</em> mutation in acute myeloid leukemia
The B-cell lymphoma 2 inhibitor venetoclax has therapeutic activity in several hematological malignancies. In acute myeloid leukemia (AML), venetoclax combined with hypomethylating agents is the standard of care for patients unfit for intensive chemotherapy, but intrinsic and acquired resistance are common. Loss of p53 function is strongly associated with venetoclax resistance, and adding venetoclax to 5-azacitidine provides no overall survival benefit in TP53-mutant AML. Other frequent...
linkinghub.elsevier.com
October 18, 2026 at 4:00 PM
Unveiling the Complete Biosynthetic Pathway of Azacitidine: A Rare 1,3,5‐Triazine Nucleoside Derived From GTP
Unveiling the Complete Biosynthetic Pathway of Azacitidine: A Rare 1,3,5‐Triazine Nucleoside Derived From GTP
The azacitidine biosynthetic gene cluster (aza BGC) was identified by the resistance-gene-guided comparative genomics method in Streptomyces mobaraensis IPIO2. The complete biosynthetic pathway of az...
onlinelibrary.wiley.com
October 6, 2026 at 9:16 PM
Full article is finally out! Venetoclax and oral azacitidine is safe and showed excellent responses in newly diagnosed AML patients.
www.sciencedirect.com/science/arti...
October 4, 2026 at 12:53 AM
📰Topline data from the phase 3 portion of the AZTOUND trial showed oral azacitidine and cedazuridine met the pharmacokinetic primary end point in patients with MDS or CMML #mpnsm #leusm #oncology

Read more: www.onclive.com/view/oral-az...
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML | OncLive
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
www.onclive.com
October 1, 2026 at 2:54 PM
#PubSaludMurcia Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML @AreaUnoArrixaca @IMIB_RMurcia
JCI Insight - Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML
2Department of Internal Medicine: Division of Genetic Medicine, The University of Michigan Medical School, Ann Arbor, United States of America
doi.org
September 25, 2026 at 10:02 AM
Correct answer C) Azacitidine plus ivosidenib
September 22, 2026 at 4:04 PM
JCI Insight - Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML insight.jci.org/articles/vie...
JCI Insight - Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML
insight.jci.org
September 16, 2026 at 12:56 PM
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia [RECRUITING]
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia [RECRUITING]
News update via NF Bot
clinicaltrials.gov
September 15, 2026 at 10:29 AM
For #BloodCancerAwarenessMonth, we are highlighting blood cancer research from across #MRCWIMM every Monday.

This week, hear from Prof Thomas Milne as he discusses his latest article in Blood on gene regulation in KMT2A rearranged acute lymphoblastic #leukaemia.

#BloodCancerResearch #AcademicSky 🧪
Blood Podcast | MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow
In this week's episode, Blood editor Dr. James Griffin interviews Drs. Thomas Milne and Dominique Bonnet on their latest articles published in volume 147 issue 24 of Blood. Dr. Milne discusses how ...
bloodpodcast.transistor.fm
September 14, 2026 at 9:04 AM
5 Azacitidine Market Size, Trends & Forecast 2035 - Wiseguy | WiseGuyReports www.wiseguyreports.com/reports/5-az...
5 Azacitidine Market Size, Trends & Forecast 2035 - Wiseguy
The 5 Azacitidine Market is expected to grow from 1,600 USD Million in 2025 to 3,500 USD Million by 2035. The 5 Azacitidine Market CAGR (growth rate) is expected to be around 8.1% | Wiseguy Reports
www.wiseguyreports.com
September 12, 2026 at 6:48 AM
🎙️ Just published a new episode of Blood Podcast: MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow. Have a listen:
MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow
In this week's episode, Blood editor Dr. James Griffin interviews Drs....
bloodpodcast.transistor.fm
September 10, 2026 at 5:47 PM